Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Demand Grows For Proton Therapy Equipment Amid Calls For More Research

This article was originally published in The Gray Sheet

Executive Summary

Burgeoning clinical adoption of resource-intensive proton radiation therapy for cancer creates unique challenges for payers, manufacturers, health care providers and patients, stakeholders say

Related Content

Radiation Oncologists Question Double-Digit Cuts To Medicare Physician Payments
Evidence Lacking On Proton Therapy For Non-Small-Cell Lung Cancer – BCBS
New Philadelphia Proton Therapy Center Promises Heavy Research Focus
Data Lacking On Proton Therapy Vs. Traditional Radiation For Cancer - AHRQ
Diagnostics Imaging Sector Hit By Hospitals’ Dwindling Access To Capital
Debate Stirs Over Medicare Coverage For Proton Therapy In Prostate Cancer
Siemens Radiation Tools Are New Destination For Calypso’s GPS For The Body
Varian Outlines Plan For Proton Therapy Market – Interview
CMS Floats Topics For Possible National Coverage Determinations
CMS Floats Topics For Possible National Coverage Determinations



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts